Novel options for the treatment of castration-resistant prostate cancer

被引：0

作者：

Carsten-H. Ohlmann

Axel S. Merseburger

Henrik Suttmann

David Schilling

Lutz Trojan

Carsten Kempkensteffen

Stefan Corvin

Michael J. Mathers

Patrick J. Bastian

机构：

[1] Saarland University,Department of Urology

[2] Hannover Medical School,Department of Urology

[3] Urologikum Hamburg,Department of Urology

[4] Eberhard-Karls-University,Department of Urology, Medical Faculty Mannheim

[5] University of Heidelberg,Department of Urology

[6] Charité,Urologische Klinik und Poliklinik

[7] University Medicine Berlin,undefined

[8] Fachzentrum für Urologie Eggenfelden,undefined

[9] PandaMED Remscheid,undefined

[10] Klinikum der Universität-Campus Großhadern,undefined

[11] Ludwig-Maximilians-Universität München,undefined

来源：

World Journal of Urology | 2012年 / 30卷

关键词：

Castration-resistant prostate cancer; Abiraterone; MDV3100; Zibotentan; Denosumab; Alpharadin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

引用

页码：495 / 503

页数：8

共 173 条

[1]

Huggins C(1942)Effect of orchiectomy and irradiation on cancer of the prostate Ann Surg 115 1192-1200

[2]

Antonarakis ES(2011)Expanding treatment options for metastatic prostate cancer N Engl J Med 364 2055-2058

[3]

Eisenberger MA(2010)EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 61-71

[4]

Heidenreich A(2001)The development of androgen-independent prostate cancer Nat Rev Cancer 1 34-45

[5]

Bellmunt J(2008)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 242-245

[6]

Bolla M(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-1520

[7]

Feldman BJ(2008)Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 6407-6415

[8]

Feldman D(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154

[9]

Berthold DR(2011)Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 813-822

[10]

Pond GR(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422

← 1 2 3 4 5 6 7 8 9 10 →